Cardiovascular disease (CVD) is prevalent worldwide and remains a leading cause of
death. Although substantial progress has been made in the diagnosis and treatment of CVD …

The potential involvement of sympathetic overactivity has been neglected in this population
despite accumulating experimental and clinical evidence suggesting a crucial role of …

Hypertension is a frequent condition encountered during kidney disease development and a
leading cause in its progression. Hallmark factors contributing to hypertension constitute a …

Written for practitioners in the field, this critically acclaimed bestseller provides authoritative
information focused on the investigation of drug-related deaths and practical approaches to …

The incidence of chronic kidney disease (CKD) is increasing worldwide, with more than 26
million people suffering from CKD in the United States alone. More patients with CKD die of …

Aims We explored the relationship between inflammation, renalase an anti-inflammatory
protein, and acute chest pain with coronary microvascular dysfunction (CMD). Methods and …

Renalase is a novel flavoprotein, highly expressed in kidney and heart, which metabolizes
catecholamines and catecholamine-like substances via a superoxide (O2–)-dependent …

Aims Renalase, an enzyme that can metabolize catecholamine, was recently reported to
attenuate the ischaemia/reperfusion (I/R)-induced cardiac injury. This work was undertaken …

Background Sympathetic overactivity and catecholamine accumulation are important
characteristic findings in heart failure, which contribute to its pathophysiology. Here, we …

Chronic kidney disease (CKD) leads to an 18-fold increase in cardiovascular complications
not fully explained by traditional risk factors. Levels of renalase, a recently discovered …